We enable nucleic acid labeling bioconjugation
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
product_variation

Our mission
We are enabling life science researchers to overcome challenges and create better solutions in diagnostics, therapeutics and vaccines development through our proprietary click chemistry

 

mRNA VACCINE DEVELOPMENT</>

Our uniqueness

baseclick’s proprietary click chemistry is the most streamlined and simplified bioconjugation method in life science. Our breakthrough in CuAAC or SPAAC, the so called click reaction, results in a convenient, versatile and reliable single step covalent coupling. The reactions require simple or no workup or purification of the product. We have developed highly efficient methods and protocols and a series of optimized ClickTech assay kits to create highly modified DNA and RNA. Our applications, customer services and tools demonstrate the superiority of patent protected platform.

Our highlights

  • Click chemistry in oligonucleotide synthesis enables labeling up to 99.99% yield.
  • The most versatile click chemistry portfolio of chemical tools including clickable dyes, sugars, fatty acids, amino acids, biotin and more to advance innovative projects
  • Our EdU cell proliferation assays provide a superior alternative to BrdU assays. For monitoring of cell vitality, determining genotoxicity or evaluating anticancer drugs.
  • Our technology enables 5’, 3’, dual, multi or internally labeled DNA or RNA sequences used in our FISH Kits and PCR Kits.
  • Click chemistry in Next Generation Sequencing enables-for the first time – complete full-length information from 5’ to 3’ in transcriptomics and is compatible with all available sequencing devices.

Our lab expertise in click chemistry of nucleic acid drug and vaccine development is also available as a service

  • Our specialized custom oligonucleotide service to produce drug substances like aptamers, siRNA and more
  • Specific cellular uptake can be achieved with mRNA clicked to targeting agents and generated via our mRNA production service

Directly to our products and services

Partner

Science

Development of a XBP1 Sequencing Kit
MILESTONE
Background:
baseclick is developing a diagnostic research tool for breast cancer, glioblastoma and prostate cancer. A very good candidate is the transcription XBP1. Expression of mutated XBP1 has been implicated in cancer progression. Its functions as transcription factor and depletion of normal XBP1 as well as expression of mutated XBP1 in cancer cells leads to cell division. Mutated XBP1 is produced in stressed cells and cancer situation when the IRE1 switches from its normal chaperon function in the ER to RNase function and unnatural cytoplasmic splicing of XBP1 mRNA occurs (XBP1s/XBP1u) leading to two forms of XBP1 protein in cancer cells. Triple-negative breast cancer (TNBC) lacks targeted therapies and has a worse prognosis than other breast cancer subtypes, underscoring an urgent need for new therapeutic targets and strategies. Our goal is to identify the best treatment for every single patient (enables personalized medicine) and monitor the treatment via transcriptome analysis.
Cooperation partner:
National University of Ireland, Galway
IRE1/XBP1 drug development
MILESTONE
Background:
The trans autophosphorylation of the kinase domain of IRE1 activates its unusual effector function, which causes the unconventional splicing of the mRNA that encodes a transcription factor XBP1. Abnormalities in XBP1 lead to ER stress and subsequently causes susceptibility for inflammatory processes that contribute to cancer. baseclick started a program whereby oligonucleotides are tested to inhibit RNase activity of IRE1 for anticancer therapy.
Cooperation partner:
National University of Ireland, Galway
Inhibition of SARS-CoV-2 replication
MILESTONE
Backgorund:
Development of RNA / DNA gene scissors for specific cleavage of viral SARS-CoV-2 genomes to inhibit viral replication. The overall goal is to design a SARS-CoV-2 drug based on an artificial gene editing method. Therefore, an oligo linked with a metal complexes capable of cutting will direct the “gene scissor” to the SARS-CoV-2 RNA in infected cells leading to inhibition of viral replication.
Cooperation partner:
Dublin City University, Ireland

The EU has funded the new Doctoral Network “MITGEST” (Quality Control of the Mitochondrial Gene Expression System in Health and Disease). Supported under the Marie

MORE →

On 28 June 2022, our CEO Dr. Thomas Frischmuth gave the lecture “Strategies to control COVID-19 pandemic and disease – nucleic acids-based vaccines and drugs”

MORE →

On 24 June 2022, our scientists Fabio Spada and Eva Schönegger will attend the workshop on New RNA Therapeutics at Center for Advanced Studies (CAS)

MORE →